Generalized Anxiety Disorder
Conditions
Interventions
None listed
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included: The primary diagnosis meets the diagnostic criteria for generalized anxiety disorder (DSM-5). Age between 18 and 65 years at the time of obtaining informed consent. Written informed consent is obtained voluntarily from the patient after receiving a sufficient explanation of the study and demonstrating adequate understanding. Usual treatment (regular consultations with a primary physician are mandatory, and the presence or absence of pharmacotherapy for generalized anxiety disorder at the time of entry is not restricted) is being provided, and no new initiation or additional changes in pharmacotherapy for generalized anxiety disorder are planned during the study period. Pharmacotherapy for generalized anxiety disorder refers to psychotropic medications such as antidepressants, anxiolytics, or hypnotics, regardless of indication. The patient is able to understand cognitive behavioral therapy and is in a mental and physical condition that allows for continuous practice for at least 16 weeks.
Exclusion criteria
Exclusion criteria: The following individuals will be excluded: Those with comorbid schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, substance-related and addictive disorders, neurocognitive disorders, or neurodevelopmental disorders. Those at imminent risk of suicide. Those with serious physical illnesses such as cancer, heart disease, or stroke. Those with intellectual disability (estimated IQ < 80 based on the JART-25: Japanese Adult Reading Test-25 or similar measures). Those who have received cognitive behavioral therapy within the past six months. Any other individuals deemed unsuitable for safe participation in this study by the principal investigator or study therapists.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of anxiety using the Hamilton Anxiety Rating Scale (HAM-A) | — |
Countries
Japan
Contacts
Public ContactItsuko Yoshida
Chiba University Cognitive Behavioral Physiology
Outcome results
None listed